Iluvien for DME poised to fulfill unmet need, create significant market niche

The Iluvien intravitreal implant will satisfy an unmet need among patients with diabetic macular edema and create sizeable new markets, Alimera Sciences officials said during a company-sponsored webcast.Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) is a non-bioerodable device designed to release fluocinolone acetonide at an initial rate of 0.25 µm per day for 36 months.